Clinical Trials Logo

Epstein-Barr Virus Infections clinical trials

View clinical trials related to Epstein-Barr Virus Infections.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06426758 Not yet recruiting - Graves Disease Clinical Trials

Graves' Disease Induced by Epstein-Barr Virus Lytic Reactivation

Start date: May 30, 2024
Phase:
Study type: Observational

Previous studies have proved that the lytic reactivation of latent Epstein-Barr virus (EBV) was significantly associated with the onset of Graves'disease (GD), however, the morbidity of GD and recurrence rate of hyperthyroidism after antithyroid drugs treatment due to lytic reactivation of EBV is not understood. We will recruit patients with newly diagnosed GD and recurrence of hyperthyroidism after antithyroid drugs treatment. In order to confirm lytic reactivation of EBV, the number of EBV DNA copies,mRNA and protein expression of immediate-early, early and late lytic EBV genes,EBV +TRAb+cells will be tested. The proportion of lytic reactivation of EBV in newly diagnosed GD and recurrence of hyperthyroidism was evaluated.

NCT ID: NCT06131489 Not yet recruiting - Clinical trials for Hemophagocytic Lymphohistiocytosis

Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement

Start date: December 1, 2023
Phase:
Study type: Observational

EBV-HLH is a rare disease with high mortality, especially for those with intestinal involvement. In order to reduce disease burden and improve survival of these patients, we conduct a prospective observational study to explore the efficacy and safety of segmental resection combined with the DEP regimen.

NCT ID: NCT06075927 Not yet recruiting - Clinical trials for Stem Cell Transplant

Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT

Start date: November 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the safety and tolerability of partial HLA-matched VSTs against both CMV and EBV viruses in recipients of allogeneic hematopoietic stem cells with refractory viral infections (CMV and/or EBV). Preliminary evaluation of the efficacy of partial HLA-matched VSTs against both CMV and EBV viruses in recipients of allogeneic hematopoietic stem cells with refractory viral infections (CMV and/or EBV); To monitor the duration and expansion of multi-virus VSTs cells after infusion.

NCT ID: NCT05970627 Not yet recruiting - Clinical trials for Adenocarcinoma of the Stomach

Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Start date: July 28, 2023
Phase: Phase 2
Study type: Interventional

This study is a prospective, single arm, multi-center phase II clinical trial designed to evaluate the efficacy and safety of perioperative SOX combined with toripalimab in participants with Epstein-Barr Virus-associated locally advanced gastric or esophagogastric junction adenocarcinoma.

NCT ID: NCT05775705 Not yet recruiting - Lymphoma Clinical Trials

L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH

Start date: August 1, 2023
Phase: Phase 3
Study type: Interventional

The efficacy and safety of L-DEP (PEG-aspargase, liposomal doxorubicin, etoposide, and methylprednisolone) regimen combined with PD-1 Antibody an induction therapy for Epstein-Barr virus (EBV)-positive lymphoma-associated hemophagocytic lymphohistiocytosis.

NCT ID: NCT04690036 Not yet recruiting - Transplant Clinical Trials

PD-1 Antibody for Reactive EBV After BMT

Start date: July 1, 2021
Phase: Early Phase 1
Study type: Interventional

PD-1 antibody for reactivation of EBV after transplantation in patients with CAEBV/EBV-HLH